ArticleTranslational oncology2026

Proof-of-concept study of clinical use of blood-based MAVS biosensor in predicting immunotherapy response in SCLC patients.

Luisa Amato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.